A phase II study of irinotecan combined with S-1 in patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy
| Autor: | Tadashi Kimura, Fuminori Kitada, Kotaro Shimura, Yuri Matsumoto, Naoko Komura, Eriko Yokoi, Aki Isobe, Seiji Mabuchi, Kenjiro Sawada, Tateki Tsutsui |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Administration Oral Uterine Cervical Neoplasms Phases of clinical research Irinotecan Gastroenterology Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Clinical endpoint Humans 030212 general & internal medicine Progression-free survival Aged Tegafur Cervical cancer Chemotherapy business.industry Obstetrics and Gynecology Middle Aged medicine.disease Survival Analysis Drug Combinations Oxonic Acid Diarrhea Treatment Outcome Oncology 030220 oncology & carcinogenesis Toxicity Female Neoplasm Recurrence Local medicine.symptom business medicine.drug |
| Zdroj: | International Journal of Gynecologic Cancer. 29:474-479 |
| ISSN: | 1525-1438 1048-891X |
| Popis: | ObjectivesWe conducted a phase II study to investigate the efficacy and toxicities of irinotecan plus oral S-1 in patients with advanced or recurrent uterine cervical cancer.MethodsPatients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy were enrolled. Irinotecan (150 mg/m2) was administered intravenously over the course of 90 min on day 1, and S-1 (80 mg/m2) was given orally in two divided doses from days 1 to 14 of a 21 day cycle. The primary endpoint of this phase II study was response rate. Secondary endpoints included safety, progression free survival, and overall survival.ResultsA total of 19 patients were enrolled and treated. The response rate was 29.4%. Grade 3–4 hematologic toxicities were observed in three patients (15.7%). The only grade 3–4 non-hematologic toxicity observed was grade 3 diarrhea. The median progression free survival and overall survival were 3 months and 9 months, respectively.ConclusionS-1 plus irinotecan in a 3 weekly setting is safe and active in women with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy. Future corroborative clinical studies are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|